Alderley Park, Cheshire, UK, 21 October 2005: - Newly released top-line results from the BOLDER II (BipOLar DEpRession) study have underlined the potential for SEROQUEL (quetiapine fumarate) in the treatment of patients with major depressive episodes associated with bipolar disorder. In BOLDER II, SEROQUEL 300mg and 600mg doses achieved a statistically significant reduction in levels of bipolar depression compared with placebo (p<0.001), as measured by the change from baseline in MADRS* total score.1
BOLDER II, an eight week, multi-centre, placebo-controlled study, reinforces the findings of the landmark BOLDER I study2 published in American Journal of Psychiatry in July 2005, which first indicated a significant effect for SEROQUEL in treating major depressive episodes associated with bipolar disorder.
In BOLDER II, the significant reduction in MADRS total score was seen both in patients with bipolar I and bipolar II disorder, in patients with or without a rapid cycling course of illness, and as early as week one after randomisation. Significant improvements were also seen compared with placebo in the various secondary study endpoints among SEROQUEL-treated patients, including reduction of anxiety symptoms. In addition, more than half (53%) of patients receiving SEROQUEL achieved remission** from their bipolar depression symptoms.
Importantly, SEROQUEL was shown to be well tolerated in BOLDER II with a similar safety profile seen to that in BOLDER I. The rate of serious adverse events was low and comparable in all treated groups. The most common adverse events reported in the trial were dry mouth, sedation, somnolence, dizziness and constipation, and there was a low incidence of treatment-emergent mania in the SEROQUEL-treated groups.
As in BOLDER I, there was a low incidence of EPS (extrapyramidal symptoms) and minimal weight change reported in the study.
* MADRS (Montgomery- sberg Depression Rating Scale) measures the sevePage: 1 2 3 Related medicine news :1
Contact: Maren Koban
Hill and Knowlton
. Childhood obesity indicates greater risk of school absenteeism, Penn study reveals2
. Penn study finds pro-death proteins required to regulate healthy immune function3
. New study shows promise in reducing surgical risks associated with surgical bleeding4
. New study counts the economic cost of persistent pain in Australia5
. UCLA researchers awarded $9M contract for study identifiying antibiotic treatment for MRSA6
. Most seniors now have drug coverage, U-M study shows7
. To gain muscle and lose fat, drink milk: study8
. Wheres the beef? Not enough of it is on elders plates, muscle-metabolism study suggests9
. Even older women at high risk have little interest in being tested for HIV, study finds10
. Metabolic study in mice could lead to good cholesterol boosters11
. Michigan-CDC study supports value of social restrictions during influenza pandemics